Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07526974) titled 'A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )' on April 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Caliway Biopharmaceuticals Co., Ltd.
Condition:
Subcutaneous Fat
Intervention:
Drug: CBL-514 Injection
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 2026
Target Sample Size: 320
Countries of Recruitment:
United States
Australia
Cana...